Cargando…
The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay
Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) can lead to long-term sequelae in males and females; however, global prevalence data vary between geographical regions, as these sexually transmitted infections are not included in routine screening. The objective of this study was to use the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816248/ https://www.ncbi.nlm.nih.gov/pubmed/36369413 http://dx.doi.org/10.1007/s10096-022-04521-5 |
_version_ | 1784864490577199104 |
---|---|
author | Perry, Michael D. Jones, Sophie Bertram, Alexander de Salazar, Adolfo Barrientos-Durán, Antonio Schiettekatte, Gilberte Lewinski, Michael Arcenas, Rodney Hansra, Avneet Njoya, Merlin García, Federico |
author_facet | Perry, Michael D. Jones, Sophie Bertram, Alexander de Salazar, Adolfo Barrientos-Durán, Antonio Schiettekatte, Gilberte Lewinski, Michael Arcenas, Rodney Hansra, Avneet Njoya, Merlin García, Federico |
author_sort | Perry, Michael D. |
collection | PubMed |
description | Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) can lead to long-term sequelae in males and females; however, global prevalence data vary between geographical regions, as these sexually transmitted infections are not included in routine screening. The objective of this study was to use the cobas(®) TV/MG assay to assess the point prevalence of TV and MG in specimens from men and women over a broad European geographical area. Urine, vaginal, endocervical, and rectal samples were collected from patients aged ≥ 18 years receiving Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) screening as per local standard of care at sites in Belgium, Germany, Spain, and the UK (Wales). Remnant samples were assessed using the cobas TV/MG assay. Analysis of 2795 samples showed that MG prevalence varied slightly across female sample types (range: 1.7–5.8%; p = 0.0042). MG prevalence was higher in male rectal samples (12.5%) than in male urine samples (3.9%; p < 0.0001). TV prevalence was low in male (0.8%; 12/1535) and female (1.3%; 16/1260) samples across all sites. Co-infection of TV/MG with CT or NG was 10.0% (19/190) and 9.6% (7/73), respectively, in both male and female samples. MG and TV prevalence rates were comparable to the published literature in Europe. MG prevalence was highest in male rectal samples; as rectal testing is an off-label use of the cobas TV/MG assay, the clinical utility of this assay for rectal testing should be further investigated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-022-04521-5. |
format | Online Article Text |
id | pubmed-9816248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-98162482023-01-07 The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay Perry, Michael D. Jones, Sophie Bertram, Alexander de Salazar, Adolfo Barrientos-Durán, Antonio Schiettekatte, Gilberte Lewinski, Michael Arcenas, Rodney Hansra, Avneet Njoya, Merlin García, Federico Eur J Clin Microbiol Infect Dis Original Article Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) can lead to long-term sequelae in males and females; however, global prevalence data vary between geographical regions, as these sexually transmitted infections are not included in routine screening. The objective of this study was to use the cobas(®) TV/MG assay to assess the point prevalence of TV and MG in specimens from men and women over a broad European geographical area. Urine, vaginal, endocervical, and rectal samples were collected from patients aged ≥ 18 years receiving Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) screening as per local standard of care at sites in Belgium, Germany, Spain, and the UK (Wales). Remnant samples were assessed using the cobas TV/MG assay. Analysis of 2795 samples showed that MG prevalence varied slightly across female sample types (range: 1.7–5.8%; p = 0.0042). MG prevalence was higher in male rectal samples (12.5%) than in male urine samples (3.9%; p < 0.0001). TV prevalence was low in male (0.8%; 12/1535) and female (1.3%; 16/1260) samples across all sites. Co-infection of TV/MG with CT or NG was 10.0% (19/190) and 9.6% (7/73), respectively, in both male and female samples. MG and TV prevalence rates were comparable to the published literature in Europe. MG prevalence was highest in male rectal samples; as rectal testing is an off-label use of the cobas TV/MG assay, the clinical utility of this assay for rectal testing should be further investigated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-022-04521-5. Springer Berlin Heidelberg 2022-11-11 2023 /pmc/articles/PMC9816248/ /pubmed/36369413 http://dx.doi.org/10.1007/s10096-022-04521-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Perry, Michael D. Jones, Sophie Bertram, Alexander de Salazar, Adolfo Barrientos-Durán, Antonio Schiettekatte, Gilberte Lewinski, Michael Arcenas, Rodney Hansra, Avneet Njoya, Merlin García, Federico The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay |
title | The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay |
title_full | The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay |
title_fullStr | The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay |
title_full_unstemmed | The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay |
title_short | The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay |
title_sort | prevalence of mycoplasma genitalium (mg) and trichomonas vaginalis (tv) at testing centers in belgium, germany, spain, and the uk using the cobas tv/mg molecular assay |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816248/ https://www.ncbi.nlm.nih.gov/pubmed/36369413 http://dx.doi.org/10.1007/s10096-022-04521-5 |
work_keys_str_mv | AT perrymichaeld theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT jonessophie theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT bertramalexander theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT desalazaradolfo theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT barrientosduranantonio theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT schiettekattegilberte theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT lewinskimichael theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT arcenasrodney theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT hansraavneet theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT njoyamerlin theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT garciafederico theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT perrymichaeld prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT jonessophie prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT bertramalexander prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT desalazaradolfo prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT barrientosduranantonio prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT schiettekattegilberte prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT lewinskimichael prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT arcenasrodney prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT hansraavneet prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT njoyamerlin prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay AT garciafederico prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay |